Ontario Cancer Institute, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada
* Author for correspondence (e-mail: jwoodget{at}uhnres.utoronto.ca)
![]() |
Summary |
---|
Key words: Signal transduction, Phosphorylation, Wnt signalling, Insulin signalling, Protein structure-function
![]() |
Introduction |
---|
Given its involvement in many pathophysiological processes and diseases, GSK-3 is a tempting therapeutic target. However, its involvement in multiple pathways also raises the issue of selectivity how might we impact one process while leaving others untouched? We must also assess the full spectrum of GSK-3 functions to avoid later surprises. For example, although inhibition of GSK-3 may be desirable in one context (e.g. in preventing neuronal apoptosis), it could have serious implications for another for example, it might accelerate hyperplasia by deregulating ß-catenin. That said, the recent development of small molecule inhibitors of GSK-3 has provided new tools for visualizing the cell from the perspective of GSK-3. Since it is highly active in most cell types, regulation of substrate phosphorylation occurs either by inactivation of GSK-3 or by changing substrate accessibility or recognition. Here, we present an overview of the various processes in which GSK-3 plays a key role and describe the current status of knowledge of GSK-3 regulation.
![]() |
GSK-3 variants |
---|
|
GSK-3 and GSK-3ß, although structurally similar, are not
functionally identical. This became obvious upon ablation of the GSK-3ß
isoform in mice, which results in an embryonic lethal phenotype
(Hoeflich et al., 2000
).
Embryos carrying homozygous deletions of exon 2 of GSK-3ß die around
embryonic day 16 owing to massive liver degeneration caused by extensive
hepatocyte apoptosis. The inability of GSK-3
to rescue the
GSK-3ß-null mice indicates that the degenerative liver phenotype arises
specifically from the loss of the beta isoform. This phenotype is remarkably
similar to that of animals lacking RelA or I-
B kinase 2
(Beg et al., 1995
;
Li et al., 1999
), components
of the NF-
B signalling pathway
(Ghosh and Karin, 2002
;
Rothwarf and Karin, 1999
).
Regulation of NF-
B nuclear import is not disrupted in embryonic
fibroblasts isolated from the GSK-3ß-null mice, which indicates that
GSK-3 affects some other level of NF-
B regulation. The specific
target(s) of GSK-3ß in the regulation of NF-
B signalling has not
been identified. Other protein kinases can phosphorylate the p65 subunit of
NF-
B, increasing transactivation
(Jang et al., 2001
;
Wang et al., 2000
).
GSK-3ß can phosphorylate the C-terminal domain (residues 354-551) of p65
in vitro (Schwabe and Brenner,
2002
), but further studies are required to verify if p65 is a
physiological GSK-3ß substrate and to assess the effect of this
modification. The phenotype of mice lacking GSK-3
has not yet been
reported.
A minor (15% of total) splice variant of GSK-3ß, GSK-3ß2,
has recently been identified and contains a 13-residue insert within the
kinase domain (Mukai et al.,
2002
). Analysis of the in vitro kinase activity of GSK-3ß2
revealed reduced activity towards the microtubule-associated protein tau,
compared with `unspliced' GSK-3ß. An antibody selective for the novel
splice-insertion polypeptide revealed that GSK-3ß2 is localized primarily
to neuronal cell bodies, unlike unspliced GSK-3ß, which is also found in
neuronal processes. It is unclear whether these substrate and subcellular
localization differences can be generalized to other proteins or cells. Given
the location of the insert within a highly conserved sequence, it probably
forms a loop/hook, which might allow differential binding of the splice
variant to scaffolding proteins that then expose the isoform to a distinct
subset of target proteins (Mukai et al.,
2002
).
![]() |
GSK-3 phosphorylation: insights from crystal structures |
---|
GSK-3 has an unusual preference for target proteins that are
pre-phosphorylated at a `priming' residue located C-terminal to the site of
GSK-3 phosphorylation (Fiol et al.,
1987). The consensus sequence for GSK-3 substrates is
Ser/ThrXXX-Ser/Thr-P, where the first Ser or Thr is the
target residue, X is any amino acid (but often Pro), and the last Ser-P/Thr-P
is the site of priming phosphorylation. Although not strictly required,
priming phosphorylation greatly increases the efficiency of substrate
phosphorylation of most GSK-3 substrates by 100-1000-fold
(Thomas et al., 1999
). For
example, glycogen synthase, the prototypical primed substrate, requires
priming phosphorylation by casein kinase II (CK2) and then undergoes
sequential multisite phosphorylation by GSK-3
(Fiol et al., 1988
;
Fiol et al., 1990
).
The function expected for the `missing' phosphothreonine in the GSK-3's T-loop is believed to be replaced by the phosphorylated residue of a primed substrate, which binds to a positively charged pocket comprising R96, R180 and K205 (residue numbers for GSK-3ß). This not only optimizes the orientation of the kinase domains but also places the substrate at the correct position within the catalytic groove for phosphorylation to occur. There are some substrates that lack a priming site. These proteins often display negatively charged residues at or near the priming position that may mimic a phospho-residue.
2) Inhibitory serine phosphorylation
Stimulation of cells with insulin causes inactivation of GSK-3 through a
phosphoinositide 3-kinase (PI 3-kinase)-dependent mechanism. PI-kinase-induced
activation of PKB (also termed Akt) results in PKB phosphorylation of both
GSK-3 isoforms (S9 of GSK-3ß; S21 of GSK-3)
(Cross et al., 1995
), which
inhibits GSK-3 activity. This leads to the dephosphorylation of substrates
including glycogen synthase and eukaryotic protein synthesis initiation
factor-2B (eIF-2B), resulting in their functional activation and consequent
increased glycogen and protein synthesis (reviewed in
Cohen et al., 1997
).
Numerous other stimuli also lead to inactivation of GSK-3 through S9/S21
phosphorylation, including growth factors such as EGF and PDGF that stimulate
the GSK-3-inactivating kinase p90RSK (also known as MAPKAP-K1)
through MAP kinases (Brady et al.,
1998; Saito et al.,
1994
), activators of p70 ribosomal S6 kinase (p70S6K) such as
amino acids, (Armstrong et al.,
2001
; Krause et al.,
2002
; Terruzzi et al.,
2002
), activators of cAMP-activated protein kinase (PKA)
(Fang et al., 2000
;
Li et al., 2000
;
Tanji et al., 2002
) and PKC
activators (Ballou et al.,
2001
; Fang et al.,
2002
).
The crystal structure of GSK-3 also helps to explain the inhibitory role of
this serine phosphorylation (see Fig.
2A). Phosphorylation of S9/S21 creates a primed pseudosubstrate
that binds intramolecularly to the positively charged pocket mentioned above.
This folding precludes phosphorylation of substrates because the catalytic
groove is occupied. Note that the mechanism of inhibition is competitive. A
consequence of this is that primed substrates, in high enough concentrations,
out-compete the pseudosubstrate and thus become phosphorylated
(Frame et al., 2001). Thus,
although less efficient, unprimed substrates may provide a more accurate
measure of GSK-3 activity in kinase assays performed in vitro. Mutation of
Arg96 to alanine disrupts the pocket of positive charge
(Fig. 2B)
(Frame et al., 2001
).
Interestingly, although a peptide of 11 residues that matches the
phosphorylated N-terminus of GSK-3ß peptide-11 competitively inhibits
both primed and unprimed substrates, a truncated version of this peptide
(NTptide-8) inhibits phosphorylation only of primed substrates
(Frame et al., 2001
). Thus,
small molecule inhibitors modeled to fit in the positively charged pocket of
the GSK-3 kinase domain could potentially be very effective for selective
inhibition of primed substrates.
|
![]() |
Physiological roles for tyrosine phosphorylation |
---|
Although GSK-3 is tyrosine phosphorylated in resting cells, the level may
not be stoichiometric. Apoptotic stimuli such as staurosporine treatment or
neurotrophic factor withdrawal increase GSK-3 activity and tyrosine
phosphorylation in certain neuronal cell lines
(Bhat et al., 2000;
Bijur and Jope, 2001
).
Moreover, LPA, through a pathway involving the G proteins
G
12 and G
13, also increases GSK-3 activity
in neuronal cells at least in part through enhanced tyrosine phosphorylation
of Y216/Y279 (Sayas et al.,
2002
). Since treatment of primary neurons with LPA results in
neurite retraction, treatment of a neuroblastoma cell line, Neuro2A, results
in cell rounding (Sayas et al.,
2002
), and LPA also causes apoptosis of adult neurons
(Steiner et al., 2000
), this
provides further circumstantial evidence for a role for tyrosine
phosphorylation in apoptosis.
Recent work has revealed two possible candidates for kinases that might
tyrosine phosphorylate GSK-3 under these circumstances. Transient increases in
intracellular calcium increase GSK-3-mediated phosphorylation of the
microtubule-associated protein tau, and the increased GSK-3 activity is
attributed to elevated GSK-3 tyrosine phosphorylation
(Hartigan and Johnson, 1999).
The tyrosine kinase that may be responsible for the phosphorylation of GSK-3
is proline-rich tyrosine kinase 2
(PYK2)
, a
calcium-sensitive enzyme. Active, but not kinase-dead, PYK2 increases tyrosine
phosphorylation of GSK-3 both in PYK2-transfected cells and in vitro, and PYK2
and GSK-3ß co-immunoprecipitate in cells transfected with PYK2
(Hartigan et al., 2001
). The
Fyn tyrosine kinase is another potential player: insulin treatment of SH-SY5Y
cells for 1 minute causes an increase in association of Fyn with GSK-3ß,
a transient increase in GSK-3ß activity with a concomitant transient
increase in GSK-3ß phosphorylation on Y216 and a transient increase in
tau phosphorylation. The short duration of insulin treatment is crucial for
the observed increase in GSK-3 activity
(Lesort et al., 1999
).
Prolonged treatment with insulin, besides the well characterized inhibition of
GSK-3 through serine phosphorylation (discussed above), has also been reported
to inhibit GSK-3 through tyrosine dephosphorylation in Chinese hamster ovary
cells (Murai et al., 1996
).
Further characterization of the proposed GSK-3-phosphorylating tyrosine
kinases is required to substantiate a role for them in physiological
processes.
The role of tyrosine phosphorylation of GSK-3 in Dictyostelium is
better understood. Zak1 is essential for activation of GSK-3 during
developmental patterning and is regulated downstream of certain cyclic AMP
receptors involved in chemotaxis (Kim et
al., 1999; Plyte et al.,
1999
). Unfortunately, identification of a mammalian orthologue of
Zak1 has so far proven elusive. Kim et al. have recently described an opposing
role for a protein tyrosine phosphatase, which dephosphorylates GSK-3 on
tyrosine residues and results in a prestalk fate
(Kim et al., 2002
).
Interestingly, phosphorylation of two tyrosine residues, both residing in the
activation loop of GSK-3, appears to be modulated by cAMP in
Dictyostelium (Kim et al.,
2002
). Both of these tyrosine residues, Y214 and Y220, are
conserved in mammals (Y216 and Y219, respectively). Thus, Y219 in
addition to Y216 might therefore play a role in GSK-3 regulation in
mammals.
![]() |
The role of GSK-3 in the Wnt/ß-catenin pathway |
---|
|
Phosphorylation of ß-catenin by GSK-3 occurs in a complex sometimes
referred to as the destruction complex, which consists minimally of the
proteins GSK-3, ß-catenin, axin/conductin and adenomatous polyposis coli
(APC) (Hinoi et al., 2000).
APC is a tumour suppressor protein commonly deleted in familial adenomatous
polyposis and sporadic colorectal cancer
(Polakis, 1997
). Axin (and a
related protein known as conductin or axil) harbors several protein-protein
interaction domains and serves as a scaffolding protein that holds together
the elements of the ß-catenin destruction complex. Both Axin and APC are
phosphorylated by GSK-3. Phosphorylation of axin by GSK-3 increases its
stability and binding to ß-catenin
(Ikeda et al., 1998
;
Jho et al., 1999
;
Yamamoto et al., 1999
).
Phosphorylation of APC increases its binding to ß-catenin
(Rubinfeld et al., 1996
).
Five groups have recently determined that ß-catenin is also a primed
substrate for GSK-3, with casein kinase I (CKI) acting as the priming kinase
(Amit et al., 2002;
Hagen et al., 2002
;
Hagen and Vidal-Puig, 2002
;
Liu et al., 2002
;
Sakanaka, 2002
;
Yanagawa et al., 2002
). CKI
phosphorylates S45, which lies four residues C-terminal to three GSK-3 targets
at serines S33, S37 and S41. As a priming kinase, CKI functions as a negative
regulator of Wnt signalling since it promotes GSK-3 function. Such a role
contrasts with that proposed in several previous reports, which identified CKI
as a positive transducer of Wnt signalling
(Gao et al., 2002
;
Kishida et al., 2001
;
Lee et al., 2001
;
McKay et al., 2001
). CKI
binds to axin and Dishevelled and phosphorylates not only ß-catenin but
also axin, Dishevelled and APC. Polakis has proposed a model in which CKI can
act as both a positive and a negative regulator of Wnt signalling
(Polakis, 2002
). In this
model, CKI plays a role in the destruction complex as the priming kinase for
GSK-3 and is required for transmission of the Wnt signal by assisting in the
activation of Dishevelled, perhaps by increasing its affinity for signalling
intermediates (see below). A novel ankyrin-repeat-containing protein,
Diversin, has been reported to recruit CKI to the destruction complex
(Schwarz-Romond et al.,
2002
).
These data raise the possibility that GSK-3 plays only a latent role in
regulation of ß-catenin. For example, if CKI activity is directly
regulated by Wnt signalling, then phosphorylation of S45 would act as the
trigger for subsequent phosphorylation by GSK-3. In this scenario, the
activity of GSK-3 could be totally independent of Wnt regulation. However,
phosphorylation of S45 appears to be constitutive, at least in some cell
types. Although S45 phosphorylation has been reported to decrease upon Wnt
stimulation, the phosphospecific antibodies used in those studies also detect
S41, one of the GSK-3 targets (Amit et al.,
2002). Antibodies selective for phosphoserine 45 do not reveal
changes in stoichiometry in response to Wnt
(Liu et al., 2002
). Clearly,
cells have evolved complex mechanisms to titrate ß-catenin levels,
presumably to allow multiple layers of control.
Another interesting player in the regulation of the Wnt pathway, at least
in vertebrates, is a GSK-3-binding protein termed GBP (also known as
FRAT)
(Farr et al., 2000
;
Ferkey and Kimelman, 2002
;
Fraser et al., 2002
;
Sumoy et al., 1999
;
Yost et al., 1998
). Binding
of GBP to GSK-3 precludes GSK-3 from binding to axin and thus interferes with
ß-catenin phosphorylation. A small peptide derived from FRAT called
FRAT-tide is sufficient to prevent axin-GSK-3 interaction and prevents
phosphorylation of both axin and ß-catenin
(Thomas et al., 1999
).
Comparison of mutations that affect binding of GSK-3 to axin and GBP, as well
as analysis of the crystal structure of a GSK-3-FRAT-tide complex, indicates
that the binding sites on GSK-3 for GBP/FRAT and axin overlap
(Bax et al., 2001
;
Ferkey and Kimelman, 2002
;
Fraser et al., 2002
).
Treatment of Xenopus embryo extracts with CKI
increases binding
of GBP to Dishevelled (Lee et al.,
2001
).
GBP also plays a role in the nuclear export of GSK-3
(Franca-Koh et al., 2002). A
mutant of GSK-3 that cannot bind to GBP accumulates in the nucleus. Moreover,
a peptide that interferes with GBP binding to GSK-3 causes endogenous GSK-3 to
accumulate in the nucleus. These findings suggest that GBP regulates access of
GSK-3 to substrates partitioned between nuclear and cytoplasmic compartments.
Since there are two known mammalian GBP homologues
(Freemantle et al., 2002
),
each with dynamically regulated expression patterns during development, GBP
could play an important role in modulating GSK-3 function, especially during
development. Rather surprisingly, GBP homologues have not been identified in
Drosophila or C. elegans, which indicates that the protein
is not a core component of canonical Wnt signalling.
A critical aspect of GSK function in the Wnt pathway is that GSK-3 appears
to be insulated from regulators of GSK-3 that lie outside of the Wnt pathway.
For example, insulin signalling leads to inhibition of GSK-3 via serine S9/S21
phosphorylation but does not cause accumulation of ß-catenin. Conversely,
Wnt signalling does not affect insulin signalling
(Ding et al., 2000;
Yuan et al., 1999
). How this
insulation occurs is unclear, but it probably stems from the effective
sequestration of a fraction of GSK-3 with axin in the destruction complex.
Note that tissues from mice lacking GSK-3ß do not show evidence of
accumulated ß-catenin even though total GSK-3 levels are reduced by 50%
and there is zero cellular GSK-3ß. Immunoprecipitation of axin from these
tissues reveals that GSK-3ß is simply replaced by GSK-3
(in
wild-type cells, both GSK-3
and GSK-3ß are found bound to axin)
(E. Rubie and J.R.W., unpublished). Since cellular levels of GSK-3 exceed
those of axin, the destruction machinery compensates for the loss of
GSK-3ß by substituting GSK-3
.
![]() |
GSK-3 and the Hedgehog pathway |
---|
![]() |
Other GSK-3 substrates |
---|
|
![]() |
Other GSK-3-binding proteins |
---|
Presenilin 1 (PS1) is one of the two mammalian presenilins identified
through association of mutations in these proteins with early-onset familial
Alzheimer's disease. Besides having a role in proteolytic processing of
proteins at the cell membrane such as amyloid precursor protein, presenilin
also binds to ß-catenin and has been implicated in regulating its
cellular levels. PS1 may also function as a scaffolding protein that binds
PKA, GSK-3 and ß-catenin (Palacino
et al., 2001). This novel quaternary complex functions in a
similar manner to the axin complex, using PS1 to couple the priming
phosphorylation by PKA (on S45 of ß-catenin) to subsequent
phosphorylation by GSK-3.
![]() |
GSK-3 and human disease |
---|
![]() |
Small molecule inhibitors of GSK-3 |
---|
Several new GSK-3 inhibitors have recently been developed, most of which
are ATP competitive (Martinez et al.,
2002a; Martinez et al.,
2002b
). A list of these drugs, their mode of action and some of
their reported effects in cell culture and patients is shown in
Table 2.
|
There may be a skeleton in the closet, however, for anti-GSK-3 therapeutics. In addition to the problem of its broad range of functions, inhibition of the enzyme could presumably lead to enhanced accumulation of ß-catenin, a known oncogene. To mitigate this complication, drugs that selectively target non-axin-associated GSK-3 would be desirable, especially for chronic diseases, such as diabetes. On the positive side, long-term lithium treatment is not associated with enhanced incidence of cancer, although the lithium-treated patient cohort is not typical of the general population.
![]() |
Perspectives |
---|
Although our understanding of GSK-3 regulation is increasing, there are
still several outstanding issues: (1) putative GSK-3 substrates need to be
verified and classified as to whether they require priming phosphorylation;
(2) proteins that have been identified as GSK-3-interacting proteins require
characterization to identify sites of interaction and mechanisms that
regulating binding; (3) the mechanism of Wnt-mediated inactivation of GSK-3
remains to be established; (4) the basis for the specific requirement for
GSK-3ß in regulating NFB function remains unclear (GSK-3
does not substitute); and (5) the specificity of newly emerging GSK-3
inhibitors must be validated.
GSK-3 has reliably and regularly provided surprises ever since its discovery, and several of these have proven to be new signalling paradigms. There is little reason to doubt that there are more revelations in store, but with enhanced tools, such as selective inhibitors, knockout mice and modified binding proteins, there is hope that the true cellular roles for this multi-talented kinase will be appreciated and its utility as a therapeutic target be realized. But there are certainly easier molecules to study...
![]() |
Acknowledgments |
---|
![]() |
Footnotes |
---|
Frequently rearranged in advanced T-cell lymphocytes
![]() |
References |
---|
Ali, A., Hoeflich, K. P. and Woodgett, J. R. (2001). Glycogen synthase kinase-3: properties, functions, and regulation. Chem. Rev. 101,2527 -2540.[CrossRef][Medline]
Amit, S., Hatzubai, A., Birman, Y., Andersen, J. S.,
Ben-Shushan, E., Mann, M., Ben-Neriah, Y. and Alkalay, I.
(2002). Axin-mediated CKI phosphorylation of beta-catenin at Ser
45: a molecular switch for the Wnt pathway. Genes Dev.
16,1066
-1076.
Armstrong, J. L., Bonavaud, S. M., Toole, B. J. and Yeaman, S.
J. (2001). Regulation of glycogen synthesis by amino acids in
cultured human muscle cells. J. Biol. Chem.
276,952
-956.
Aza-Blanc, P., Ramirez-Weber, F. A., Laget, M. P., Schwartz, C. and Kornberg, T. B. (1997). Proteolysis that is inhibited by hedgehog targets Cubitus interruptus protein to the nucleus and converts it to a repressor. Cell 89,1043 -1053.[Medline]
Ballou, L. M., Tian, P. Y., Lin, H. Y., Jiang, Y. P. and Lin, R.
Z. (2001). Dual regulation of glycogen synthase kinase-3beta
by the alpha1A-adrenergic receptor. J. Biol. Chem.
276,40910
-40916.
Barker, N., Morin, P. J. and Clevers, H. (2000). The Yin-Yang of TCF/beta-catenin signaling. Adv. Cancer Res. 77,1 -24.[Medline]
Bax, B., Carter, P. S., Lewis, C., Guy, A. R., Bridges, A., Tanner, R., Pettman, G., Mannix, C., Culbert, A. A., Brown, M. J. et al. (2001). The structure of phosphorylated GSK-3beta complexed with a peptide, FRATtide, that inhibits beta-catenin phosphorylation. Structure (Camb) 9,1143 -1152.[CrossRef][Medline]
Beals, C. R., Sheridan, C. M., Turck, C. W., Gardner, P. and
Crabtree, G. R. (1997). Nuclear export of NF-ATc enhanced by
glycogen synthase kinase-3. Science
275,1930
-1934.
Beg, A. A., Sha, W. C., Bronson, R. T., Ghosh, S. and Baltimore, D. (1995). Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature 376,167 -170.[CrossRef][Medline]
Bellon, S., Fitzgibbon, M. J., Fox, T., Hsiao, H. M. and Wilson, K. P. (1999). The structure of phosphorylated p38gamma is monomeric and reveals a conserved activation-loop conformation. Structure Fold. Des. 7,1057 -1065.[Medline]
Benjamin, W. B., Pentyala, S. N., Woodgett, J. R., Hod, Y. and Marshak, D. (1994). ATP citrate-lyase and glycogen synthase kinase-3 beta in 3T3-L1 cells during differentiation into adipocytes. Biochem J. 300,477 -482.[Medline]
Bhat, R. V., Shanley, J., Correll, M. P., Fieles, W. E., Keith,
R. A., Scott, C. W. and Lee, C. M. (2000). Regulation and
localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta
in cellular and animal models of neuronal degeneration. Proc. Natl.
Acad. Sci. USA 97,11074
-11079.
Bijur, G. N. and Jope, R. S. (2001).
Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3
beta. J. Biol. Chem.
276,37436
-37442.
Bourouis, M., Moore, P., Ruel, L., Grau, Y., Heitzler, P. and Simpson, P. (1990). An early embryonic product of the gene shaggy encodes a serine/threonine protein kinase related to the CDC28/cdc2+ subfamily. EMBO J. 9,2877 -2884.[Abstract]
Boyle, W. J., Smeal, T., Defize, L. H., Angel, P., Woodgett, J. R., Karin, M. and Hunter, T. (1991). Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity. Cell 64,573 -584.[Medline]
Brady, M. J., Bourbonais, F. J. and Saltiel, A. R.
(1998). The activation of glycogen synthase by insulin switches
from kinase inhibition to phosphatase activation during adipogenesis in 3T3-L1
cells. J. Biol. Chem.
273,14063
-14066.
Brantjes, H., Barker, N., van Es, J. and Clevers, H. (2002). TCF: Lady Justice casting the final verdict on the outcome of Wnt signalling. Biol. Chem. 383,255 -261.[Medline]
Breton, J. J. and Chabot-Fletcher, M. C.
(1997). The natural product hymenialdisine inhibits interleukin-8
production in U937 cells by inhibition of nuclear factor-kappaB. J.
Pharmacol. Exp. Ther. 282,459
-466.
Brown, N. R., Noble, M. E., Endicott, J. A. and Johnson, L. N. (1999). The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nat. Cell Biol. 1,438 -443.[CrossRef][Medline]
Canagarajah, B. J., Khokhlatchev, A., Cobb, M. H. and Goldsmith, E. J. (1997). Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell 90,859 -869.[Medline]
Carmichael, J., Sugars, K. L., Bao, Y. and Rubinsztein, D.
C. (2002). GSK-3beta inhibitors prevent cellular
polyglutamine toxicity caused by the Huntington's disease mutation.
J. Biol. Chem. 277,33791
-33798.
Chen, G., Huang, L. D., Jiang, Y. M. and Manji, H. K. (1999). The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J. Neurochem. 72,1327 -1230.[CrossRef][Medline]
Chu, B., Soncin, F., Price, B. D., Stevenson, M. A. and
Calderwood, S. K. (1996). Sequential phosphorylation by
mitogen-activated protein kinase and glycogen synthase kinase 3 represses
transcriptional activation by heat shock factor-1. J. Biol.
Chem. 271,30847
-30857.
Coghlan, M. P., Culbert, A. A., Cross, D. A., Corcoran, S. L., Yates, J. W., Pearce, N. J., Rausch, O. L., Murphy, G. J., Carter, P. S., Roxbee Cox, L. et al. (2000). Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. 7, 793-803.[CrossRef][Medline]
Cohen, P., Alessi, D. R. and Cross, D. A. (1997). PDK1, one of the missing links in insulin signal transduction? FEBS Lett. 410, 3-10.[CrossRef][Medline]
Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M. and Hemmings, B. A. (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378,785 -789.[CrossRef][Medline]
Cross, D. A., Culbert, A. A., Chalmers, K. A., Facci, L., Skaper, S. D. and Reith, A. D. (2001). Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J. Neurochem. 77, 94-102.[CrossRef][Medline]
Dajani, R., Fraser, E., Roe, S. M., Young, N., Good, V., Dale, T. C. and Pearl, L. H. (2001). Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 105,721 -732.[CrossRef][Medline]
Damiens, E., Baratte, B., Marie, D., Eisenbrand, G. and Meijer, L. (2001). Anti-mitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest. Oncogene 20,3786 -37897.[CrossRef][Medline]
De Ferrari, G. V. and Inestrosa, N. C. (2000). Wnt signaling function in Alzheimer's disease. Brain Res Rev 33,1 -12.[Medline]
De Sarno, P., Li, X. and Jope, R. S. (2002). Regulation of Akt and glycogen synthase kinase-3beta phosphorylation by sodium valproate and lithium. Neuropharmacology 43,1158 -1164.[CrossRef][Medline]
Dent, P., Campbell, D. G., Hubbard, M. J. and Cohen, P. (1989). Multisite phosphorylation of the glycogen-binding subunit of protein phosphatase-1G by cyclic AMP-dependent protein kinase and glycogen synthase kinase-3. FEBS Lett. 248, 67-72.[CrossRef][Medline]
Dent, P., Lavoinne, A., Nakielny, S., Caudwell, F. B., Watt, P. and Cohen, P. (1990). The molecular mechanism by which insulin stimulates glycogen synthesis in mammalian skeletal muscle. Nature 348,302 -308.[CrossRef][Medline]
Detera-Wadleigh, S. D. (2001). Lithium-related genetics of bipolar disorder. Ann. Med. 33,272 -285.[Medline]
Diehl, J. A., Cheng, M., Roussel, M. F. and Sherr, C. J.
(1998). Glycogen synthase kinase-3beta regulates cyclin D1
proteolysis and subcellular localization. Genes Dev.
12,3499
-3511.
Dierick, H. and Bejsovec, A. (1999). Cellular mechanisms of wingless/Wnt signal transduction. Curr. Top. Dev. Biol. 43,153 -190.[Medline]
Ding, V. W., Chen, R. H. and McCormick, F.
(2000). Differential regulation of glycogen synthase kinase 3beta
by insulin and Wnt signaling. J. Biol. Chem.
275,32475
-32481.
Eldar-Finkelman, H. (2002). Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol. Med. 8,126 -132.[CrossRef][Medline]
Eldar-Finkelman, H. and Krebs, E. G. (1997).
Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3
impairs insulin action. Proc. Natl. Acad. Sci. USA
94,9660
-9664.
Embi, N., Rylatt, D. B. and Cohen, P. (1980). Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur. J. Biochem. 107,519 -527.[Medline]
Fang, X., Yu, S., Tanyi, J. L., Lu, Y., Woodgett, J. R. and
Mills, G. B. (2002). Convergence of multiple signaling
cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation
and inactivation by lysophosphatidic acid through a protein kinase C-dependent
intracellular pathway. Mol. Cell. Biol.
22,2099
-2110.
Fang, X., Yu, S. X., Lu, Y., Bast, R. C., Jr, Woodgett, J. R.
and Mills, G. B. (2000). Phosphorylation and inactivation of
glycogen synthase kinase 3 by protein kinase A. Proc. Natl. Acad.
Sci. USA 97,11960
-11965.
Farr, G. H., 3rd, Ferkey, D. M., Yost, C., Pierce, S. B.,
Weaver, C. and Kimelman, D. (2000). Interaction among GSK-3,
GBP, axin, and APC in Xenopus axis specification. J. Cell
Biol. 148,691
-702.
Ferkey, D. M. and Kimelman, D. (2002). Glycogen
synthase kinase-3 beta mutagenesis identifies a common binding domain for GBP
and Axin. J. Biol. Chem.
277,16147
-16152.
Fiol, C. J., Mahrenholz, A. M., Wang, Y., Roeske, R. W. and
Roach, P. J. (1987). Formation of protein kinase recognition
sites by covalent modification of the substrate. Molecular mechanism for the
synergistic action of casein kinase II and glycogen synthase kinase 3.
J. Biol. Chem. 262,14042
-14048.
Fiol, C. J., Haseman, J. H., Wang, Y. H., Roach, P. J., Roeske, R. W., Kowalczuk, M. and DePaoli-Roach, A. A. (1988). Phosphoserine as a recognition determinant for glycogen synthase kinase-3: phosphorylation of a synthetic peptide based on the G-component of protein phosphatase-1. Arch. Biochem. Biophys. 267,797 -802.[Medline]
Fiol, C. J., Wang, A., Roeske, R. W. and Roach, P. J.
(1990). Ordered multisite protein phosphorylation. Analysis of
glycogen synthase kinase 3 action using model peptide substrates.
J. Biol. Chem. 265,6061
-6065.
Fiol, C. J., Williams, J. S., Chou, C. H., Wang, Q. M., Roach,
P. J. and Andrisani, O. M. (1994). A secondary
phosphorylation of CREB341 at Ser129 is required for the cAMP-mediated control
of gene expression. A role for glycogen synthase kinase-3 in the control of
gene expression. J. Biol. Chem.
269,32187
-32193.
Forlenza, O. V., Spink, J. M., Dayanandan, R., Anderton, B. H., Olesen, O. F. and Lovestone, S. (2000). Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3beta inhibition and in neurons. J. Neural. Transm. 107,1201 -1212.[CrossRef]
Frame, S. and Cohen, P. (2001). GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 359,1 -16.[CrossRef][Medline]
Frame, S., Cohen, P. and Biondi, R. M. (2001). A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol. Cell 7,1321 -1327.[CrossRef][Medline]
Franca-Koh, J., Yeo, M., Fraser, E., Young, N. and Dale, T.
C. (2002). The regulation of glycogen synthase Kinse-3
nuclear export by Frat/GBP. J. Biol. Chem.
277,43844
-43848.
Fraser, E., Young, N., Dajani, R., Franca-Koh, J., Ryves, J.,
Williams, R. S., Yeo, M., Webster, M. T., Richardson, C., Smalley, M. J. et
al. (2002). Identification of the Axin and Frat binding
region of glycogen synthase kinase-3. J. Biol. Chem.
277,2176
-2185.
Freemantle, S. J., Portland, H. B., Ewings, K., Dmitrovsky, F., DiPetrillo, K., Spinella, M. J. and Dmitrovsky, E. (2002). Characterization and tissue-specific expression of human GSK-3-binding proteins FRAT1 and FRAT2. Gene 291, 17-27.[CrossRef][Medline]
Gao, Z. H., Seeling, J. M., Hill, V., Yochum, A. and Virshup, D.
M. (2002). Casein kinase I phosphorylates and destabilizes
the beta-catenin degradation complex. Proc. Natl. Acad. Sci.
USA 99,1182
-1187.
Ghosh, S. and Karin, M. (2002). Missing pieces in the NF-kappaB puzzle. Cell 109,S81 -96.[Medline]
Gould, T. D. and Manji, H. K. (2002). The Wnt
signaling pathway in bipolar disorder. Neuroscientist
8, 497-511.
Grimes, C. A. and Jope, R. S. (2001). The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog. Neurobiol. 65,391 -426.[CrossRef][Medline]
Hagen, T. and Vidal-Puig, A. (2002). Characterisation of the phosphorylation of beta-catenin at the GSK-3 priming site Ser45. Biochem. Biophys. Res. Commun. 294,324 -328.[CrossRef][Medline]
Hagen, T., di Daniel, E., Culbert, A. A. and Reith, A. D.
(2002). Expression and characterization of GSK-3 mutants and
their effect on beta-catenin phosphorylation in intact cells. J.
Biol. Chem. 277,23330
-23335.
Hall, A. C., Brennan, A., Goold, R. G., Cleverley, K., Lucas, F. R., Gordon-Weeks, P. R. and Salinas, P. C. (2002). Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons. Mol. Cell. Neurosci. 20,257 -270.[CrossRef][Medline]
Hanger, D. P., Hughes, K., Woodgett, J. R., Brion, J. P. and Anderton, B. H. (1992). Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett. 147,58 -62.[CrossRef][Medline]
Hartigan, J. A. and Johnson, G. V. (1999).
Transient increases in intracellular calcium result in prolonged
site-selective increases in Tau phosphorylation through a glycogen synthase
kinase 3beta-dependent pathway. J. Biol. Chem.
274,21395
-21401.
Hartigan, J. A., Xiong, W. C. and Johnson, G. V. (2001). Glycogen synthase kinase 3beta is tyrosine phosphorylated by PYK2. Biochem. Biophys. Res. Commun. 284,485 -489.[CrossRef][Medline]
Hers, I., Tavare, J. M. and Denton, R. M. (1999). The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31-8220) are potent inhibitors of glycogen synthase kinase-3 activity. FEBS Lett. 460,433 -436.[CrossRef][Medline]
Hinoi, T., Yamamoto, H., Kishida, M., Takada, S., Kishida, S.
and Kikuchi, A. (2000). Complex formation of adenomatous
polyposis coli gene product and axin facilitates glycogen synthase kinase-3
beta-dependent phosphorylation of beta-catenin and down-regulates
beta-catenin. J. Biol. Chem.
275,34399
-34406.
Hoeflich, K. P., Luo, J., Rubie, E. A., Tsao, M. S., Jin, O. and Woodgett, J. R. (2000). Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 406,86 -90.[CrossRef][Medline]
Huelsken, J. and Behrens, J. (2002). The Wnt
signalling pathway. J. Cell Sci.
115,3977
-3978.
Hughes, K., Ramakrishna, S., Benjamin, W. B. and Woodgett, J. R. (1992). Identification of multifunctional ATP-citrate lyase kinase as the alpha-isoform of glycogen synthase kinase-3. Biochem. J. 288,309 -314.[Medline]
Hughes, K., Nikolakaki, E., Plyte, S. E., Totty, N. F. and Woodgett, J. R. (1993). Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J. 12,803 -808.[Abstract]
Ikeda, S., Kishida, S., Yamamoto, H., Murai, H., Koyama, S. and
Kikuchi, A. (1998). Axin, a negative regulator of the Wnt
signaling pathway, forms a complex with GSK-3beta and beta-catenin and
promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO
J. 17,1371
-1384.
Ilouz, R., Kaidanovich, O., Gurwitz, D. and Eldar-Finkelman, H. (2002). Inhibition of glycogen synthase kinase-3beta by bivalent zinc ions: insight into the insulin-mimetic action of zinc. Biochem. Biophys. Res. Commun. 295,102 -106.[CrossRef][Medline]
Ingham, P. W. and McMahon, A. P. (2001).
Hedgehog signaling in animal development: paradigms and principles.
Genes Dev. 15,3059
-3087.
Jang, M. K., Goo, Y. H., Sohn, Y. C., Kim, Y. S., Lee, S. K.,
Kang, H., Cheong, J. and Lee, J. W. (2001).
Ca2+/calmodulin-dependent protein kinase IV stimulates nuclear factor-kappa B
transactivation via phosphorylation of the p65 subunit. J. Biol.
Chem. 276,20005
-20010.
Jho, E., Lomvardas, S. and Costantini, F. (1999). A GSK3beta phosphorylation site in axin modulates interaction with beta-catenin and Tcf-mediated gene expression. Biochem. Biophys. Res. Commun 266, 28-35.[CrossRef][Medline]
Jia, J., Amanai, K., Wang, G., Tang, J., Wang, B. and Jiang, J. (2002). Shaggy/GSK3 antagonizes Hedgehog signalling by regulating Cubitus interruptus. Nature 416,548 -452.[CrossRef][Medline]
Johnson, R. L., Rothman, A. L., Xie, J., Goodrich, L. V., Bare, J. W., Bonifas, J. M., Quinn, A. G., Myers, R. M., Cox, D. R., Epstein, E. H., Jr et al. (1996). Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 272,1668 -1671.[Abstract]
Kaidanovich, O. and Eldar-Finkelman, H. (2002). The role of glycogen synthase kinase-3 in insulin resistance and Type 2 diabetes. Expert Opin. Ther. Targets 6, 555-561.[Medline]
Khaled, M., Larribere, L., Bille, K., Aberdam, E., Ortonne, J.
P., Ballotti, R. and Bertolotto, C. (2002). Glycogen synthase
kinase 3b is activated by cAMP and plays an active role in the regulation of
melanogenesis. J. Biol. Chem.
277,33690
-33697.
Kim, L., Harwood, A. and Kimmel, A. R. (2002). Receptor-dependent and tyrosine phosphatase-mediated inhibition of GSK3 regulates cell fate choice. Dev. Cell 3, 523-532.[Medline]
Kim, L., Liu, J. and Kimmel, A. R. (1999). The novel tyrosine kinase ZAK1 activates GSK3 to direct cell fate specification. Cell 99,399 -408.[Medline]
Kirschenbaum, F., Hsu, S. C., Cordell, B. and McCarthy, J.
V. (2001). Glycogen synthase kinase-3beta regulates
presenilin 1 C-terminal fragment levels. J. Biol.
Chem. 276,30701
-30707.
Kishida, M., Hino, S., Michiue, T., Yamamoto, H., Kishida, S.,
Fukui, A., Asashima, M. and Kikuchi, A. (2001). Synergistic
activation of the Wnt signaling pathway by Dvl and casein kinase Iepsilon.
J. Biol. Chem. 276,33147
-33155.
Klein, P. S. and Melton, D. A. (1996). A
molecular mechanism for the effect of lithium on development. Proc.
Natl. Acad. Sci. USA 93,8455
-8459.
Knockaert, M., Wieking, K., Schmitt, S., Leost, M., Grant, K.
M., Mottram, J. C., Kunick, C. and Meijer, L. (2002).
Intracellular targets of Paullones. Identification following affinity
purification on immobilized inhibitor. J. Biol. Chem.
277,25493
-25501.
Krause, U., Bertrand, L., Maisin, L., Rosa, M. and Hue, L.
(2002). Signalling pathways and combinatory effects of insulin
and amino acids in isolated rat hepatocytes. Eur. J.
Biochem. 269,3742
-3750.
Leclerc, S., Garnier, M., Hoessel, R., Marko, D., Bibb, J. A.,
Snyder, G. L., Greengard, P., Biernat, J., Wu, Y. Z., Mandelkow, E. M. et
al. (2001). Indirubins inhibit glycogen synthase kinase-3
beta and CDK5/p25, two protein kinases involved in abnormal tau
phosphorylation in Alzheimer's disease. A property common to most
cyclin-dependent kinase inhibitors? J. Biol. Chem.
276,251
-260.
Lee, E., Salic, A. and Kirschner, M. W. (2001).
Physiological regulation of [beta]-catenin stability by Tcf3 and CK1epsilon.
J. Cell Biol. 154,983
-993.
Leost, M., Schultz, C., Link, A., Wu, Y. Z., Biernat, J.,
Mandelkow, E. M., Bibb, J. A., Snyder, G. L., Greengard, P., Zaharevitz, D. W.
et al. (2000). Paullones are potent inhibitors of glycogen
synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur. J.
Biochem. 267,5983
-5994.
Lesort, M., Jope, R. S. and Johnson, G. V. (1999). Insulin transiently increases tau phosphorylation: involvement of glycogen synthase kinase-3beta and Fyn tyrosine kinase. J. Neurochem. 72,576 -584.[CrossRef][Medline]
Li, M., Wang, X., Meintzer, M. K., Laessig, T., Birnbaum, M. J.
and Heidenreich, K. A. (2000). Cyclic AMP promotes neuronal
survival by phosphorylation of glycogen synthase kinase 3beta. Mol.
Cell. Biol. 20,9356
-9363.
Li, Q., van Antwerp, D., Mercurio, F., Lee, K. F. and Verma, I.
M. (1999). Severe liver degeneration in mice lacking the
IkappaB kinase 2 gene. Science
284,321
-325.
Li, X., Bijur, G. N. and Jope, R. S. (2002). Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection. Bipolar Disord. 4,137 -144.[CrossRef][Medline]
Li, Y., Bharti, A., Chen, D., Gong, J. and Kufe, D.
(1998). Interaction of glycogen synthase kinase 3beta with the
DF3/MUC1 carcinoma-associated antigen and beta-catenin. Mol. Cell.
Biol. 18,7216
-7224.
Liu, C., Li, Y., Semenov, M., Han, C., Baeg, G. H., Tan, Y., Zhang, Z., Lin, X. and He, X. (2002). Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108,837 -847.[Medline]
Lochhead, P. A., Coghlan, M., Rice, S. Q. and Sutherland, C.
(2001). Inhibition of GSK-3 selectively reduces
glucose-6-phosphatase and phosphatase and phosphoenolypyruvate carboxykinase
gene expression. Diabetes
50,937
-946.
Maccioni, R. B., Munoz, J. P. and Barbeito, L. (2001). The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Arch. Med. Res. 32,367 -381.[CrossRef][Medline]
Manji, H. K., Moore, G. J. and Chen, G. (1999). Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol. Psychiatry 46,929 -940.[CrossRef][Medline]
Manoukian, A. S. and Woodgett, J. R. (2002). Role of glycogen synthase kinase-3 in cancer: regulation by Wnts and other signaling pathways. Adv. Cancer Res. 84,203 -229.[Medline]
Martinek, S., Inonog, S., Manoukian, A. S. and Young, M. W. (2001). A role for the segment polarity gene shaggy/GSK-3 in the Drosophila circadian clock. Cell 105,769 -779.[CrossRef][Medline]
Martinez, A., Alonso, M., Castro, A., Perez, C. and Moreno, F. J. (2002a). First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem. 45,1292 -1299.[CrossRef][Medline]
Martinez, A., Castro, A., Dorronsoro, I. and Alonso, M. (2002b). Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med. Res. Rev. 22,373 -384.[CrossRef][Medline]
Mattson, M. P. (2001). Neuronal death and GSK-3beta: a tau fetish? Trends Neurosci. 24,255 -256.
McKay, R. M., Peters, J. M. and Graff, J. M. (2001). The casein kinase I family in Wnt signaling. Dev. Biol. 235,388 -396.[CrossRef][Medline]
Meijer, L., Thunnissen, A. M., White, A. W., Garnier, M., Nikolic, M., Tsai, L. H., Walter, J., Cleverley, K. E., Salinas, P. C., Wu, Y. Z. et al. (2000). Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol. 7,51 -63.[CrossRef][Medline]
Mettey, Y., Gompel, M., Thomas, V., Garnier, M., Leost, M., Ceballos-Picot, I., Noble, M., Endicott, J., Vierfond, J. M. and Meijer, L. (2003). Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J. Med. Chem. 46,222 -236.[CrossRef][Medline]
Miller, J. R. (2002). The Wnts. Genome Biol. 3, REVIEWS3001.
Morfini, G., Szebenyi, G., Elluru, R., Ratner, N. and Brady, S.
T. (2002). Glycogen synthase kinase 3 phosphorylates kinesin
light chains and negatively regulates kinesin-based motility. EMBO
J. 21,281
-293.
Mukai, F., Ishiguro, K., Sano, Y. and Fujita, S. C. (2002). Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3beta. J. Neurochem. 81,1073 -1083.[CrossRef][Medline]
Murai, H., Okazaki, M. and Kikuchi, A. (1996). Tyrosine dephosphorylation of glycogen synthase kinase-3 is involved in its extracellular signal-dependent inactivation. FEBS Lett. 392,153 -160.[CrossRef][Medline]
Novak, A. and Dedhar, S. (1999). Signaling through beta-catenin and Lef/Tcf. Cell Mol. Life Sci. 56,523 -537.[CrossRef][Medline]
Palacino, J. J., Murphy, M. P., Murayama, O., Iwasaki, K.,
Fujiwara, M., Takashima, A., Golde, T. E. and Wolozin, B.
(2001). Presenilin 1 regulates beta-catenin-mediated
transcription in a glycogen synthase kinase-3-independent fashion.
J. Biol. Chem. 276,38563
-38569.
Park, I. K., Roach, P., Bondor, J., Fox, S. P. and
DePaoli-Roach, A. A. (1994). Molecular mechanism of the
synergistic phosphorylation of phosphatase inhibitor-2. Cloning, expression,
and site-directed mutagenesis of inhibitor-2. J. Biol.
Chem. 269,944
-954.
Plyte, S. E., O'Donovan, E., Woodgett, J. R. and Harwood, A.
J. (1999). Glycogen synthase kinase-3 (GSK-3) is regulated
during Dictyostelium development via the serpentine receptor cAR3.
Development 126,325
-333.
Polakis, P. (1997). The adenomatous polyposis coli (APC) tumor suppressor. Biochim. Biophys. Acta 1332,F127 -F147.[CrossRef][Medline]
Polakis, P. (2000). Wnt signaling and cancer.
Genes Dev. 14,1837
-1851.
Polakis, P. (2002). Casein Kinase 1: A Wnt'er of disconnect. Curr. Biol. 12, R499.[CrossRef][Medline]
Price, M. A. and Kalderon, D. (2002). Proteolysis of the Hedgehog signaling effector Cubitus interruptus requires phosphorylation by Glycogen Synthase Kinase 3 and Casein Kinase 1. Cell 108,823 -835.[Medline]
Pulverer, B. J., Fisher, C., Vousden, K., Littlewood, T., Evan, G. and Woodgett, J. R. (1994). Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. Oncogene 9,59 -70.[Medline]
Rothwarf, D. M. and Karin, M. (1999). The NF-kappa B activation pathway: a paradigm in information transfer from membrane to nucleus. Sci STKE 1999, RE1.
Rubinfeld, B., Albert, I., Porfiri, E., Fiol, C., Munemitsu, S. and Polakis, P. (1996). Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 272,1023 -1026.[Abstract]
Ruiz i Altaba, A. (1999) Gli proteins and Hedgehog signaling: development and cancer. Trends Genet. 15,418 -425.[CrossRef][Medline]
Ryves, W. J. and Harwood, A. J. (2001). Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem. Biophys. Res. Commun. 280,720 -725.[CrossRef][Medline]
Ryves, W. J., Dajani, R., Pearl, L. and Harwood, A. J. (2002). Glycogen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites. Biochem. Biophys. Res. Commun. 290,967 -972.[CrossRef][Medline]
Saito, Y., Vandenheede, J. R. and Cohen, P. (1994). The mechanism by which epidermal growth factor inhibits glycogen synthase kinase 3 in A431 cells. Biochem. J. 303, 27-31.[Medline]
Sakanaka, C. (2002). Phosphorylation and regulation of beta-catenin by casein kinase I epsilon. J. Biochem. (Tokyo) 132,697 -703.[Abstract]
Sayas, C. L., Avila, J. and Wandosell, F.
(2002). Glycogen synthase kinase-3 is activated in neuronal cells
by galpha 12 and galpha 13 by rho-independent and rho-dependent mechanisms.
J. Neurosci. 22,6863
-6875.
Schwabe, R. F. and Brenner, D. A. (2002). Role
of glycogen synthase kinase-3 in TNF-alpha-induced NF-kappaB activation and
apoptosis in hepatocytes. Am. J. Physiol. Gastrointest. Liver
Physiol. 283,G204
-G211.
Schwarz-Romond, T., Asbrand, C., Bakkers, J., Kuhl, M.,
Schaeffer, H. J., Huelsken, J., Behrens, J., Hammerschmidt, M. and Birchmeier,
W. (2002). The ankyrin repeat protein Diversin recruits
Casein kinase Iepsilon to the beta-catenin degradation complex and acts in
both canonical Wnt and Wnt/JNK signaling. Genes Dev.
16,2073
-2084.
Sears, R., Nuckolls, F., Haura, E., Taya, Y., Tamai, K. and
Nevins, J. R. (2000). Multiple Ras-dependent phosphorylation
pathways regulate Myc protein stability. Genes Dev.
14,2501
-2514.
Seidensticker, M. J. and Behrens, J. (2000). Biochemical interactions in the wnt pathway. Biochim. Biophys. Acta 1495,168 -182.[Medline]
Sharpe, C., Lawrence, N. and Martinez Arias, A. (2001). Wnt signalling: a theme with nuclear variations. Bioessays 23,311 -318.[CrossRef][Medline]
Siegfried, E. and Perrimon, N. (1994). Drosophila wingless: a paradigm for the function and mechanism of Wnt signaling. Bioessays 16,395 -404.[Medline]
Siegfried, E., Perkins, L. A., Capaci, T. M. and Perrimon, N. (1990). Putative protein kinase product of the Drosophila segment-polarity gene zeste-white3. Nature 345,825 -829.[CrossRef][Medline]
Singh, L. P., Denslow, N. D. and Wahba, A. J. (1996). Modulation of rabbit reticulocyte guanine nucleotide exchange factor activity by casein kinases 1 and 2 and glycogen synthase kinase 3. Biochemistry 35,3206 -3212.[CrossRef][Medline]
Smalley, M. J. and Dale, T. C. (1999). Wnt signalling in mammalian development and cancer. Cancer Metastasis Rev. 18,215 -230.[CrossRef][Medline]
Smith, D. G., Buffet, M., Fenwick, A. E., Haigh, D., Ife, R. J., Saunders, M., Slingsby, B. P., Stacey, R. and Ward, R. W. (2001). 3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg. Med. Chem. Lett. 11,635 -639.[CrossRef][Medline]
Stambolic, V., Ruel, L. and Woodgett, J. R. (1996). Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr. Biol. 6,1664 -1668.[Medline]
Steiner, M. R., Holtsberg, F. W., Keller, J. N., Mattson, M. P.
and Steiner, S. M. (2000). Lysophosphatidic acid induction of
neuronal apoptosis and necrosis. Ann. N Y Acad. Sci.
905,132
-141.
Sumoy, L., Kiefer, J. and Kimelman, D. (1999). Conservation of intracellular Wnt signaling components in dorsal-ventral axis formation in zebrafish. Dev. Genes Evol. 209, 48-58.[CrossRef][Medline]
Taipale, J. and Beachy, P. A. (2001). The Hedgehog and Wnt signalling pathways in cancer. Nature 411,349 -354.[CrossRef][Medline]
Takeda, K., Takemoto, C., Kobayashi, I., Watanabe, A., Nobukuni,
Y., Fisher, D. E. and Tachibana, M. (2000). Ser298 of MITF, a
mutation site in Waardenburg syndrome type 2, is a phosphorylation site with
functional significance. Hum. Mol. Genet.
9, 125-132.
Tanji, C., Yamamoto, H., Yorioka, N., Kohno, N., Kikuchi, K. and
Kikuchi, A. (2002). A-kinase anchoring protein AKAP220 binds
to glycogen synthase kinase-3beta (GSK-3beta) and mediates protein kinase
A-dependent inhibition of GSK-3beta. J. Biol. Chem.
277,36955
-36961.
ter Haar, E., Coll, J. T., Austen, D. A., Hsiao, H. M., Swenson, L. and Jain, J. (2001). Structure of GSK3beta reveals a primed phosphorylation mechanism. Nat. Struct. Biol. 8, 593-596.[CrossRef][Medline]
Terruzzi, I., Allibardi, S., Bendinelli, P., Maroni, P., Piccoletti, R., Vesco, F., Samaja, M. and Luzi, L. (2002). Amino acid- and lipid-induced insulin resistance in rat heart: molecular mechanisms. Mol. Cell. Endocrinol. 190,135 -145.[CrossRef][Medline]
Thomas, G. M., Frame, S., Goedert, M., Nathke, I., Polakis, P. and Cohen, P. (1999). A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of axin and beta-catenin. FEBS Lett. 458,247 -251.[CrossRef][Medline]
van Noort, M., Meeldijk, J., van der Zee, R., Destree, O. and
Clevers, H. (2002). Wnt signaling controls the
phosphorylation status of beta-catenin. J. Biol. Chem.
277,17901
-17905.
Wang, Q. M., Fiol, C. J., DePaoli-Roach, A. A. and Roach, P.
J. (1994). Glycogen synthase kinase-3 beta is a dual
specificity kinase differentially regulated by tyrosine and serine/threonine
phosphorylation. J. Biol. Chem.
269,14566
-14574.
Wang, D., Westerheide, S. D., Hanson, J. L. and Baldwin, A. S.,
Jr (2000). Tumor necrosis factor alpha-induced
phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II.
J. Biol. Chem. 275,32592
-32597.
Watcharasit, P., Bijur, G. N., Zmijewski, J. W., Song, L.,
Zmijewska, A., Chen, X., Johnson, G. V. and Jope, R. S.
(2002). Direct, activating interaction between glycogen synthase
kinase-3beta and p53 after DNA damage. Proc. Natl. Acad. Sci.
USA 99,7951
-7955.
Welsh, G. I. and Proud, C. G. (1993). Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B. Biochem. J. 294,625 -629.[Medline]
Williams, R. S., Cheng, L., Mudge, A. W. and Harwood, A. J. (2002). A common mechanism of action for three mood-stabilizing drugs. Nature 417,292 -295.[CrossRef][Medline]
Woodgett, J. R. (1990). Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 9,2431 -2438.[Abstract]
Woodgett, J. R. (2001). Judging a protein by more than its name: GSK-3. Sci STKE 2001,RE12 .
Woodgett, J. R. and Cohen, P. (1984). Multisite phosphorylation of glycogen synthase. Molecular basis for the substrate specificity of glycogen synthase kinase-3 and casein kinase-II (glycogen synthase kinase-5). Biochim. Biophys. Acta 788,339 -347.[Medline]
Yamamoto, H., Kishida, S., Kishida, M., Ikeda, S., Takada, S.
and Kikuchi, A. (1999). Phosphorylation of axin, a Wnt signal
negative regulator, by glycogen synthase kinase-3beta regulates its stability.
J. Biol. Chem. 274,10681
-10684.
Yanagawa, S., Matsuda, Y., Lee, J. S., Matsubayashi, H., Sese,
S., Kadowaki, T. and Ishimoto, A. (2002). Casein kinase I
phosphorylates the Armadillo protein and induces its degradation in
Drosophila. EMBO J. 21,1733
-1742.
Yost, C., Farr, G. H., 3rd, Pierce, S. B., Ferkey, D. M., Chen, M. M. and Kimelman, D. (1998). GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis. Cell 93,1031 -1041.[Medline]
Yost, C., Torres, M., Miller, J. R., Huang, E., Kimelman, D. and Moon, R. T. (1996). The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev. 10,1443 -1454.[Abstract]
Yuan, H., Mao, J., Li, L. and Wu, D. (1999).
Suppression of glycogen synthase kinase activity is not sufficient for
leukemia enhancer factor-1 activation. J. Biol. Chem.
274,30419
-30423.
Related articles in JCS: